Filing Flows › Nuvation Bio (NUVB) › Q1 2025
Nuvation Bio (NUVB) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
Nuvation Bio (NUVB) reported revenue of $3.1M for the first quarter 2025 (Q1 2025) and -46% from the quarter before.
Nuvation Bio, Q1 2025: revenue $3.1M, net loss $53.2M, operating cash flow −$42.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.1M | -46% | — |
| Operating profit | −$59.0M | — | — |
| Net earnings | −$53.2M | — | — |
| Operating cash flow | −$42.6M | — | — |
What changed
Revenue was $3.1M in Q1 2025, down 46% from the previous quarter. Research and Development Service Revenue was the largest line at 67% of revenue.
Gross margin was 32.1%. Operating costs exceeded revenue by $59.0M, an operating margin of -1913.2%. The quarter ended with a net loss of $53.2M, wider than the previous quarter's $49.4M loss.
Operating cash flow was −$42.6M. Non-cash charges added back $310K of depreciation and amortization and $7.9M of share-based compensation. Working capital and other items added $2.4M.
Questions
What was Nuvation Bio's revenue in the first quarter 2025?
Nuvation Bio (NUVB) reported revenue of $3.1M for the first quarter 2025 (Q1 2025) and -46% from the quarter before.
Source: Nuvation Bio 10-Q on SEC EDGAR.